Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) ·
Monoamine releasing agent (9) ·
GABAA positive allosteric modulator (8) ·
CB1/CB2 agonist (7) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Potent 5-HT2A agonist (5) ·
LSD analogue; 5-HT2A agonist (4) ·
Prodrug of LSD; 5-HT2A agonist (4) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
NMDA antagonist (2) ·
Prodrug of GHB (2)
uses:
None (131) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) ·
'"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1) ·
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)
starting dose:
None (131) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)
preparations:
None (131) ·
100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) ·
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) ·
100 U/mL FlexTouch pen, vial (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
duration:
halflife:
None (131) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) ·
~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) ·
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)
bioavailability:
None (131) ·
Not formally characterized in humans. (1) ·
~100% from subcutaneous depot (1) ·
~100% from subcutaneous depot (by definition of the route) (1) ·
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)
pregnancy:
None (131) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 135 results in range #1 to #135.
1
2
- 2-AI
- 2-FA
- 2-FDCK
- 2-FMA
- 25B-NBOH
- 25B-NBOMe
- 25C-NBOH
- 25C-NBOMe
- 25I-NBOH
- 25I-NBOMe
- 25N-NBOMe
- 2C-B-FLY
- 2C-C
- 2C-D
- 2C-E
- 2C-I
- 2C-P
- 2C-T-2
- 2C-T-7
3
4
5
A
B
C
D
E
F
G
H
I
J
L
M
- MCPP
- MDPV
- Mephedrone
- MET
- Methallylescaline
- Methcathinone
- Methoxetamine
- Methylnaphthidate
- Methylone
- Metizolam
- Mexedrone
- MiPLA
- MiPT